ArticleJournal of palliative medicine2018

Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.

Jason D Doles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.